Angiotensin receptor blockers and the risk of malignancy: A note of caution

Drug Safety

Volumn 33, Issue 9, 2010, Pages 709-712

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; PLACEBO; RESERPINE;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG RESEARCH; EDITORIAL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH; RISK;

EID: 77955562688     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11532450-000000000-00000     Document Type: Editorial

References (14)

1. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627-636
2. Horwitz RI, Feinstein AR. Exclusion bias and the false re-lationship of reserpine and breast cancer. Arch Intern Med 1985; 145: 1873-1875
3. Coleman CI, Baker WL, Kluger J, et al. Antihypertensivemedication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008; 26: 622-629
4. Pahor M, Furberg CD. Is the use of some calcium ant-agonists linked to cancer? Evidence from recent observational studies. Drugs Aging 1998; 13: 99-108
5. Leenen FH, Nwachuku CE, Black HR, et al. Clinical eventsin high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48: 374-384
6. Effect of enalapril on mortality and development of heartfailure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-691
7. Maschio G, Alberti D, Janin G, et al. Effect of the angio-tensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945
8. Grossman E, Messerli FH, Goldbourt U. Antihypertensivetherapy and the risk of malignancies. Eur Heart J 2001; 22: 1343-1352
9. Friis S, Felmeden DC, Lip GY. Antihypertensive therapyand cancer risk. Drug Saf 2001; 24: 727-739
10. Boehringer Ingelheim affirms safety of telmisartan with ananalysis of 50,000 patients and strongly disagrees with the publication of Sipahi et al. in Lancet Oncology June 2010 [press release; online]. Available from URL http://us. boehringer-ingelheim.com/newsroom/2010/06-13-10-tel-safety.html [Accessed 2010 Jul 10]
11. European Medicines Agency. Meeting highlights from theCommittee for Medicinal Products for Human Use (CHMP) [online]. Available from URL: http://www.ema. europa.eu/pdfs/human/press/pr/27209310en.pdf [Accessed 2010 Jul 10]
12. Angiotensin receptor blockers (ARBs): ongoing safety re-view for cancer risk [online]. Available from URL http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm219185.htm [Accessed 2010 Jul 20]
13. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hy-pertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031
14. Julius S, Kjeldsen SE, Weber MA. Angiotensin-receptorblockade and the risk of cancer: omission of VALUEtrial data invalidates conclusions [letter]. Lancet Oncol. In Press